BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 22416035)

  • 1. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
    Williamson CT; Kubota E; Hamill JD; Klimowicz A; Ye R; Muzik H; Dean M; Tu L; Gilley D; Magliocco AM; McKay BC; Bebb DG; Lees-Miller SP
    EMBO Mol Med; 2012 Jun; 4(6):515-27. PubMed ID: 22416035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
    Williamson CT; Muzik H; Turhan AG; Zamò A; O'Connor MJ; Bebb DG; Lees-Miller SP
    Mol Cancer Ther; 2010 Feb; 9(2):347-57. PubMed ID: 20124459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
    Weston VJ; Oldreive CE; Skowronska A; Oscier DG; Pratt G; Dyer MJ; Smith G; Powell JE; Rudzki Z; Kearns P; Moss PA; Taylor AM; Stankovic T
    Blood; 2010 Nov; 116(22):4578-87. PubMed ID: 20739657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
    Kubota E; Williamson CT; Ye R; Elegbede A; Peterson L; Lees-Miller SP; Bebb DG
    Cell Cycle; 2014; 13(13):2129-37. PubMed ID: 24841718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
    Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
    Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
    Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
    Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
    Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
    Bryant HE; Helleday T
    Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
    BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
    Gilardini Montani MS; Prodosmo A; Stagni V; Merli D; Monteonofrio L; Gatti V; Gentileschi MP; Barilà D; Soddu S
    J Exp Clin Cancer Res; 2013 Nov; 32(1):95. PubMed ID: 24252502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between DNA double-strand break rejoining and cell survival after exposure to ionizing radiation in human fibroblast strains with differing ATM/p53 status: implications for evaluation of clinical radiosensitivity.
    Mirzayans R; Severin D; Murray D
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1498-505. PubMed ID: 17126209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
    van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
    J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.
    Löser DA; Shibata A; Shibata AK; Woodbine LJ; Jeggo PA; Chalmers AJ
    Mol Cancer Ther; 2010 Jun; 9(6):1775-87. PubMed ID: 20530711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.
    Schoonen PM; Kok YP; Wierenga E; Bakker B; Foijer F; Spierings DCJ; van Vugt MATM
    Mol Oncol; 2019 Nov; 13(11):2422-2440. PubMed ID: 31529615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents.
    Haince JF; Kozlov S; Dawson VL; Dawson TM; Hendzel MJ; Lavin MF; Poirier GG
    J Biol Chem; 2007 Jun; 282(22):16441-53. PubMed ID: 17428792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
    Liu Q; Gheorghiu L; Drumm M; Clayman R; Eidelman A; Wszolek MF; Olumi A; Feldman A; Wang M; Marcar L; Citrin DE; Wu CL; Benes CH; Efstathiou JA; Willers H
    Oncogene; 2018 May; 37(21):2793-2805. PubMed ID: 29511347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors target ATM+p53-defective gastric cancer.
    Curtin NJ
    Cell Cycle; 2014; 13(20):3161-2. PubMed ID: 25485492
    [No Abstract]   [Full Text] [Related]  

  • 19. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
    Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of Wip1 partially rescues Atm deficiency phenotypes in mice.
    Darlington Y; Nguyen TA; Moon SH; Herron A; Rao P; Zhu C; Lu X; Donehower LA
    Oncogene; 2012 Mar; 31(9):1155-65. PubMed ID: 21765465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.